Exiqon announces presentation of results at the 2011 ASCO Annual meeting in
Chicago showing the potential use of microRNAs as biomarkers in drug
development together with a major pharmaceutical company and the National
Cancer Center, SingaporeExiqon A/S (Copenhagen:EXQ) today announced that results from a diagnostic
program on the potential of using circulating microRNAs in serum as companion
diagnostic biomarkers has been selected for presentation at the 2011 ASCO
meeting to be held June 3-6 in Chicago.

The title of the work is: “The potential of circulating microRNA (miRNA) levels
as a biomarker in drug development: An analysis of tumor-serum samples from
patients on a phase I trial of saracatinib-paclitaxel (P) carboplatin (C)”.
Abstract No: 10548 Citation: J Clin Oncol 29: 2011 (suppl; abstr 10548).

“The selection for presentation at the ASCO is a reflection of the great
progress being made in demonstrating the utility of miRNAs present in blood
derived serum or plasma as biomarkers.”, says Adam Baker, VP of Diagnostics at
Exiqon.

For more information, please visit the 2011 ASCO Annual Meeting home page at:
http://chicago2011.asco.org/

Abstract page: http://abstract.asco.org/AbstView_102_78314.html

Please see the full press release in the attached PDF-file.

PressRelease_May2011_ASCO.pdf